Drug
Inca034176
Inca034176: highest development phase Phase 3, developed by Incyte. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Incyte
Trials
| Drug | Phase | Indication |
|---|---|---|
| INCA034176 NCT06585774 | Phase 3 | Chronic Graft-versus-host-disease |
Latest
No recent events.
Follow Inca034176 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.